Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Podcasts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Podcasts
  • Subscriptions

Bevacizumab shows survival benefit for non-small lung cancer patients who received subsequent pemetrexed treatment but not had a therapeutic effect in clinical practice

Nobuyuki Koyama, Shohei Minesaki, Susumu Yamazaki, Harue Utsugi, Yuri Maeno, Tetsuya Okano, Yoshitake Murayama, Kunihiko Kobayashi
European Respiratory Journal 2012 40: P2913; DOI:
Nobuyuki Koyama
1Respiratory Medicine, Saitama Medical University International Medical Center, Hidaka-shi, Saitama, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shohei Minesaki
1Respiratory Medicine, Saitama Medical University International Medical Center, Hidaka-shi, Saitama, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Susumu Yamazaki
1Respiratory Medicine, Saitama Medical University International Medical Center, Hidaka-shi, Saitama, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Harue Utsugi
1Respiratory Medicine, Saitama Medical University International Medical Center, Hidaka-shi, Saitama, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yuri Maeno
1Respiratory Medicine, Saitama Medical University International Medical Center, Hidaka-shi, Saitama, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tetsuya Okano
1Respiratory Medicine, Saitama Medical University International Medical Center, Hidaka-shi, Saitama, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yoshitake Murayama
1Respiratory Medicine, Saitama Medical University International Medical Center, Hidaka-shi, Saitama, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kunihiko Kobayashi
1Respiratory Medicine, Saitama Medical University International Medical Center, Hidaka-shi, Saitama, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • PDF
Loading

Abstract

[Backgound] Bevacizumab (BEV), a humanized monoclonal antibody against vascular endothelial growth factor, is one of molecular targeting agents for non-small lung cancer (NSCLC). The aim of this study is to evaluate the efficacy of BEV in clinical practice. [Methods] We retrospectively investigated the clinicopathological characteristics of 26 NSCLC patietnts who had undergone BEV therapy in Saitama Medical University International Medical Center and Saitama Medical University Hospital. [Results] The patients had a median age of 64 years (range, 33 to 75 years), and 19 males and current smokers. Epidermal growth factor receptor gene mutations were found in 6 patients (23%). Combined with BEV, each half of 26 patients received the chemotherapeutic regimen of either carboplatin/paclitaxel or carboplatin/pemetrexed. Objective response rate was 54% and disease control rate was 96%, and median progression free survival and overall survival were 100 days and 202 days, respectively. Adverse events included 4% of arrhythmia, 27% of hypertension, 8% of lower gastrointestinal bleeding, 19% of nasal bleeding, and 23% of proteinuria. Using Kaplan-Meier survival curves and logrank tests, therapeutic response influenced neither progression free survival nor overall survival, whereas longer overall survival was observed in NSCLC patients treated with pemetrexed-containing chemotherapy after failure of BEV. [Conclusion] Therapeutic response to BEV does not predict survival benefit of BEV-treated NSCLC patients. Meanwhile, pemetrexed may be a novel therapeutic option for NSCLC patients who have failed BEV treatment.

  • Lung cancer / Oncology
  • Thoracic oncology
  • Treatments
  • © 2012 ERS
Previous
Back to top
Vol 40 Issue Suppl 56 Table of Contents
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Bevacizumab shows survival benefit for non-small lung cancer patients who received subsequent pemetrexed treatment but not had a therapeutic effect in clinical practice
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Bevacizumab shows survival benefit for non-small lung cancer patients who received subsequent pemetrexed treatment but not had a therapeutic effect in clinical practice
Nobuyuki Koyama, Shohei Minesaki, Susumu Yamazaki, Harue Utsugi, Yuri Maeno, Tetsuya Okano, Yoshitake Murayama, Kunihiko Kobayashi
European Respiratory Journal Sep 2012, 40 (Suppl 56) P2913;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Bevacizumab shows survival benefit for non-small lung cancer patients who received subsequent pemetrexed treatment but not had a therapeutic effect in clinical practice
Nobuyuki Koyama, Shohei Minesaki, Susumu Yamazaki, Harue Utsugi, Yuri Maeno, Tetsuya Okano, Yoshitake Murayama, Kunihiko Kobayashi
European Respiratory Journal Sep 2012, 40 (Suppl 56) P2913;
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
  • Info & Metrics
  • PDF
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

  • Lung adenocarcinoma mimicking interstitial lung disease showed good response to navelbine monotherapy
  • Should preoperative FDG uptake on PET/CT guide postoperative surveillance in surgical non-small cell lung cancer (NSCLC)
  • Pemetrexed in maintenance therapy of 164 patients with advanced non-small-cell lung cancer (NSCLC)
Show more 11.1 Lung Cancer

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERJ

  • Journal information
  • Editorial board
  • Reviewers
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • Podcasts
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN:  0903-1936
Online ISSN: 1399-3003

Copyright © 2023 by the European Respiratory Society